● CLOSED
BTC60,639
+0.00 (+1.04%)
|
ETH1,713
+0.00 (+2.03%)
|
SOL70.33
-0.00 (-0.39%)
|
BNB556.63
+0.00 (+1.65%)
|
XRP0.9289
-0.00 (-0.09%)
|
ADA0.1443
-0.00 (-0.35%)
|
BTC60,639
+0.00 (+1.04%)
|
ETH1,713
+0.00 (+2.03%)
|
SOL70.33
-0.00 (-0.39%)
|
BNB556.63
+0.00 (+1.65%)
|
XRP0.9289
-0.00 (-0.09%)
|
ADA0.1443
-0.00 (-0.35%)
|
Invest Daily

Stock Analysis: JNJ

Johnson & Johnson

JNJ · Healthcare · Pharmaceuticals

Johnson & Johnson is a global healthcare company that researches, develops, and manufactures a wide range of products in the pharmaceutical and medical technology fields. The company operates through two primary segments: Innovative Medicine and MedTech.

Hold

Fair Value Summary

Current Price

$270.47

Fair Value

$297.91

Margin of Safety

+9.2%

52-Week Range

$199.91 – $290.25

Scenario Price Targets

Bear Case

$138.20

Base Case

$311.73

Bull Case

$856.63

How We Built This Fair Value

DCF (10-yr)(40% weight)
$307.80
Forward P/E(35% weight)
$388.99
Graham Number(15% weight)
$70.81
Analyst Target(10% weight)
$280.18
Blended Fair Value$297.91

Why “Hold”?

JNJ trades near its blended fair value of $297.91, based on DCF, P/E, and Graham models.

The fundamentals are supported by positive free cash flow, low leverage, 16% net margins.

This is a research output, not personalized investment advice.

Save this JNJ analysis to your inbox

Get this full report emailed to you so you can revisit it anytime, plus a weekly note with undervalued stock ideas. Free, no credit card.

We'll only email you about JNJ and your weekly brief. Unsubscribe anytime.

Your JNJ analysis is ready

Save this report or share it before you scroll on. The full breakdown is below.

Track JNJ to check back later

Save this stock to your dashboard so you can revisit it without searching. Free to analyze; sign in to save.

Share this analysis

How fragile is this fair value?

Nudge expected growth by 3 points and the discount rate by 1 point, and JNJ's DCF value moves between $197.66 and $541.01 (base $311.73). This range covers the DCF model only, not the blended fair value above.

Unlock the full sensitivity table

Pro also adds the Investment Committee's five framework stress tests on this thesis.

Financial Health

Revenue

$99.3B

Net Income

$16.1B

Free Cash Flow

$20.6B

Gross Margin

67.8%

Operating Margin

26.6%

Net Margin

16.2%

ROE

20.0%

ROIC

21.6%

Debt/Equity

0.55

Current Ratio

1.02

Revenue Growth

5.9%

P/E Ratio

41.1

Forward P/E

24.3

PEG Ratio

3.43

Dividend Yield

1.97%

Beta

0.20

Top 3 Risk Factors

Dividend Sustainability

Payout ratio of 81% is high - dividend may be at risk if earnings decline.

Pro feature30-day money-back guarantee · $70/year

JNJ's dividend sustainability was flagged as a risk.

Dividend Safety Scorer Quantifies whether the dividend survives a downturn: payout coverage, free-cash-flow backing, and balance-sheet strength, scored 0-100.

Stress-test the dividend Start Pro, risk-free for 30 days

Know what a stock is worth before you buy it.

Five valuation models, an AI research analyst, and an all-account wealth dashboard. $70 a year — a fraction of one research subscription.

30-day money-back guarantee · Cancel in one click · Secure checkout by Stripe